EN3835

BIOLOGICAL9 trials

Conditions

Adhesive CapsulitisCelluliteEdematous Fibrosclerotic Panniculopathy (Cellulite)Edematous Fibrosclerotic Panniculopathy (EFP)Fibroids, UterineFrozen ShoulderLedderhose DiseaseLeiomyoma

Phase 1

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

CompletedNCT02889848

Advance Biofactures CorporationFibroids, Uterine, Leiomyoma

Start: 2016-10-27End: 2018-11-15Updated: 2019-07-10

Phase 2

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

TerminatedNCT04209530

Endo PharmaceuticalsCellulite, Edematous Fibrosclerotic Panniculopathy (EFP)

Start: 2019-11-20End: 2020-10-05Updated: 2021-10-07

Safety and Efficacy of EN3835 in Participants With Frozen Shoulder

CompletedNCT04496167

Endo PharmaceuticalsAdhesive Capsulitis, Frozen Shoulder

Start: 2020-07-29End: 2022-04-14Updated: 2023-09-13

Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

CompletedNCT05152173

Endo PharmaceuticalsPlantar Fibromatosis

Start: 2021-11-29End: 2023-01-10Updated: 2026-03-27

Phase 3

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

CompletedNCT03428750

Endo PharmaceuticalsEdematous Fibrosclerotic Panniculopathy (Cellulite)

Start: 2018-02-05End: 2018-09-26Updated: 2020-10-08

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

CompletedNCT03446781

Endo PharmaceuticalsEdematous Fibrosclerotic Panniculopathy (Cellulite)

Start: 2018-02-08End: 2018-09-26Updated: 2020-10-08

Real World CCH Study in Adult Females With Cellulite

CompletedNCT04170296

Endo PharmaceuticalsCellulite, Edematous Fibrosclerotic Panniculopathy (EFP)

Start: 2019-11-01End: 2021-01-08Updated: 2022-02-22

Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

CompletedNCT05254457

Endo PharmaceuticalsPlantar Fibromatosis

Start: 2022-02-14End: 2024-03-21Updated: 2025-03-21

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

CompletedNCT06151197

Endo USA Inc., a Keenova Therapeutics CompanyLedderhose Disease, Plantar Fibromatosis

Start: 2023-11-28End: 2026-06-09Updated: 2026-07-13

Related Papers

Collagenase Clostridium Histolyticum (CCH) in Patients with Plantar Fibromatosis (PFI): Post Hoc Analysis of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study

Foot & Ankle Orthopaedics2025-10-01

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess Collagenase Clostridium Histolyticum vs Placebo in Patients With Plantar Fibromatosis

Foot & Ankle Orthopaedics2024-10-01

Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids

Clinical and Translational Medicine2021-07-0145 citations